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Human African trypanosomiasis has not been reported in 
Nigeria since 2012. Nevertheless, limitations of current sur-
veillance programs mean that undetected infections may 
persist. We report a recent case of stage 2 trypanosomiasis 
caused by Trypanosoma brucei gambiense acquired in Ni-
geria and imported into the United Kingdom.
Human African trypanosomiasis (HAT), known as Af-rican sleeping sickness, is a protozoal infection, the 
West African form of which is caused by Trypanosoma 
brucei gambiense. We report a case of imported T. brucei 
gambiense HAT, acquired in Nigeria, where no cases have 
been reported since 2012 (1).
The case-patient, a 58-year-old Nigerian woman, 
lived near Warri, in Delta State, Nigeria. She traveled in-
frequently to towns within Delta State, across the Niger 
River into Bayelsa State, and to larger cities in Nigeria, 
but never outside Nigeria. She reported no history of tse-
tse fly bites.
In January 2016, the patient experienced leg tremors 
and lethargy. These symptoms persisted until arrival in the 
United Kingdom in May 2016. Over the next 2 months, 
increasing malaise and unsteadiness in walking developed. 
In August 2016, the patient was admitted to a regional hos-
pital with confusion and drowsiness. She was febrile at 
admission but had no lymphadenopathy; neurologic exami-
nation revealed no neck stiffness or photophobia, but did 
show poor coordination with slow cognitive processes.
Laboratory investigations revealed microcytic anemia 
with a C-reactive protein level of 13 mg/L (reference val-
ue <5 mg/L) and a total serum IgM of 13.7 g/L (reference 
range 0.5–2.0 g/L). A blood film was negative for malaria. 
Confirmatory assays after positive screening assay results 
for HIV and syphilis antibodies showed the original results 
to be false positive.
Cerebrospinal fluid (CSF) examination revealed 331 
leukocytes/mm3, 99% lymphocytes; CSF protein level 0.82 
g/L (reference range 0.23–0.38 g/L); and glucose level was 
>50% plasma glucose. Results of CSF PCR for herpesvi-
ruses, enterovirus, and JC virus were negative. Results of 
GeneXpert (Cepheid, Buckinghamshire, UK) tests of CSF 
and mycobacterial culture were negative. Magnetic reso-
nance imaging of the brain showed, on T2 weighted and 
flair images, bilateral diffuse hyperintensities within white 
matter located in the periventricular regions, basal ganglia, 
cerebellum, and brainstem.
Treatment with ceftriaxone, acyclovir, antitubercu-
lous treatment and prednisolone was stopped at 14 days 
because of a lack of clinical improvement and drug-in-
duced transaminitis.
The patient’s lethargy, intermittent confusion, and pe-
riods of somnolence became more severe. Examination 
in August 2016 revealed intention tremor in all limbs and 
myoclonic jerks. Her case was discussed with the Imported 
Fever Service at Public Health England. A serum sample 
was sent to the Hospital of Tropical Diseases in London, 
UK for T. brucei gambiense indirect fluorescent antibody 
testing (IFAT), which showed a positive result (titer 1:400). 
The patient was transferred to this hospital.
Repeat CSF examination revealed a protein level of 
1.14 g/L, CSF glucose level of 2.3 mmol/L (serum 5.5 
mmol/L), and 1,140 leukocytes/mm3 (90% mononuclear). 
No trypanosomes were seen in the buffy coat of peripheral 
blood or CSF. CSF total IgM of 1.98 mg/L (reference range 
0–0.9 mg/L) and IgG of 306 mg/L (reference range 10–40 
mg/L) were markedly raised (2).
T. brucei gambiense IFAT results for CSF (titer 1:4) 
and blood (titer 1:400) were positive. DNA extracted 
from CSF was positive for trypanosomes of the subge-
nus Trypanozoon by PCR (3) and confirmed as T. brucei 
gambiense group 1 by diagnostic PCR with TgsGP prim-
ers (4). The result of immune trypanolysis was negative 
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when T. brucei gambiense variable antigen type LiTat 
1.3 was used but positive when using LiTat 1.5 (4). The 
patient had a titer of 1:32 in the CATT/T. brucei gam-
biense test (5,6).
We administered nifurtimox/eflornithine combina-
tion therapy, according to World Health Organization 
guidelines, for treatment of stage 2 T. brucei gambiense. 
By the end of treatment, the patient’s cognitive function, 
myoclonus, tremor, and ataxia had all improved, and she 
was discharged.
A posttreatment CSF examination revealed 4 leuko-
cytes/mm3 and a protein level of 1.17 g/L. Six months after 
discharge, the patient had made a full functional recovery. 
Repeat CSF examination revealed 4 leukocytes/mm3 and 
a protein level of 0.63 g/L, and MRI of the brain showed 
improvement. The CSF T. brucei gambiense IFAT titer de-
clined to 1:2.
No cases of HAT in Nigeria have been reported to the 
World Health Organization since 2012 (1). The last report-
ed patients were from the Abraka region, in Delta State, 
≈50 km from this case-patient’s residence (7). We do not 
have a clear exposure time for this patient, which is likely 
to have been within 2–3 years before her hospitalization, 
although we have reported a case-patient with an exposure 
>29 years prior to illness onset; the emerging scientific con-
sensus is that trypanotolerance may exist among some in-
fected patients, leading to delay in diagnosis and premature 
confidence of disease elimination (8,9).
A clue to diagnosis, alongside clinical and travel his-
tory, was a high serum IgM level, a prominent feature in 
T. brucei gambiense–infected patients, as a result of poly-
clonal B-cell activation (10). False-positive antibody test 
results specific for pathogens have been reported; multiple 
positive antibody tests may aid the clinician in considering 
HAT as a differential diagnosis (10).
This case shows that HAT transmission continues in 
Nigeria and surveillance in Delta state is warranted. There 
may be a role for additional diagnostic tools if we are to 
achieve the goal of eliminating HAT by 2030.
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